Revlimid

Active substance

lenalidomide

Holder

Celgene sprl

Status

closed

Indication

diffuse large B cell lymphoma in patients who already received at least two prior treatment lines

Public documents

Approbation

Information for the patient

Informed consent

Last update

29/06/2022

Last updated on 13/02/2024